Quality-adjusted time without symptoms or toxicity (Q-TWiST) for lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma

بواسطة C. H. Lee, Y. Wan, A. Smith, R. Xie, R. J. Motzer
منشور في 2022-02-01